This is a huge relief for the millions of patients and doctors in developing countries who depend on affordable medicines from India, and for treatment providers like MSF. The SC decision now makes patents on the medicines that we desperately need less likely. This marks the strongest possible signal to Novartis and other multinational pharmaceutical companies that they should stop seeking to attack the Indian patent law

Unni Karunakara | INTERNATIONAL PRESIDENT, MSF

The judgment is a victory for patients both in India and around the world. We are pleased with the judgment which prevents the use of frivolous patents to deny access to medicines for patients

Y K Hamied | CHAIRMAN, CIPLA

It gives the much required boost to Indian generics, which were being throttled in many ways.

Daara Patel | SECRETARY GENERAL, INDIAN DRUG MANUFACTURERS’ ASSOCIATION

The SC verdict is a landmark judgment which will not only affect Glivec but will avoid patenting of older compounds and avoid ever-greening of patented products. More than that, it will make anti-cancer life-saving drugs affordable and consequently result in saving many lives. And this will happen not only in India but in over 75 other countries where India exports generic drugs

Y K Sapru | CHAIRMAN & CEO, CANCER PATIENTS AID ASSOCIATION

It is a historic judgment which reaffirms the position of the Indian law and in particular, provisions of Section 3(d) of the Patents Act which mandates the need for a substantive innovation while deciding on a case for grant of a fresh patent. Indian Patent Law is fully in conformity with our international obligations under the TRIPS agreement

Anand Sharma | COMMERCE AND INDUSTRY MINISTER (2013)